This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiesner, J.
Right arrow Articles by Jomaa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiesner, J.
Right arrow Articles by Jomaa, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2002, p. 2889-2894, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.2889-2894.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro and In Vivo Synergy of Fosmidomycin, a Novel Antimalarial Drug, with Clindamycin

Jochen Wiesner,1,2* Dajana Henschker,2 David B. Hutchinson,2,{dagger} Ewald Beck,1 and Hassan Jomaa2

Institute of Biochemistry, Academic Hospital Centre, Justus-Liebig-University,1 Jomaa Pharmaka GmbH, D-35392 Giessen, Germany2

Received 7 January 2002/ Returned for modification 3 May 2002/ Accepted 11 June 2002

Fosmidomycin acts through inhibition of 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, a key enzyme of the nonmevalonate pathway of isoprenoid biosynthesis. It possesses potent antimalarial activity in vitro and in murine malaria. In a recent clinical study, fosmidomycin was effective and well tolerated in the treatment of patients with acute uncomplicated Plasmodium falciparum malaria but resulted in an unacceptably high rate of recrudescence. In order to identify a potential combination partner, the interaction of fosmidomycin with a number of antimalarial drugs in current use was investigated in a series of in vitro experiments. Synergy was observed between fosmidomycin and the lincosamides, lincomycin and clindamycin. The efficacy of a combination of fosmidomycin and clindamycin was subsequently demonstrated in the Plasmodium vinckei mouse model.

* Corresponding author. Mailing address: Jomaa Pharmaka GmbH, Frankfurter Strasse 50, D-35392 Giessen, Germany. Phone: 49-641-797070. Fax: 49-641-7970710. E-mail: Jochen.Wiesner{at}Jomaa.de.

{dagger} Present address: Betsoms Farmhouse, Westerham, Kent, TN16 2DR, United Kingdom.

Antimicrobial Agents and Chemotherapy, September 2002, p. 2889-2894, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.2889-2894.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tahar, R., Basco, L. K. (2007). Molecular Epidemiology of Malaria in Cameroon. XXV. In Vitro Activity of Fosmidomycin and its Derivatives against Fresh Clinical Isolates of Plasmodium falciparum and Sequence Analysis of 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase. Am J Trop Med Hyg 77: 214-220 [Abstract] [Full Text]  
  • Oyakhirome, S., Issifou, S., Pongratz, P., Barondi, F., Ramharter, M., Kun, J. F., Missinou, M. A., Lell, B., Kremsner, P. G. (2007). Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum Malaria. Antimicrob. Agents Chemother. 51: 1869-1871 [Abstract] [Full Text]  
  • Benoit-Vical, F., Lelievre, J., Berry, A., Deymier, C., Dechy-Cabaret, O., Cazelles, J., Loup, C., Robert, A., Magnaval, J.-F., Meunier, B. (2007). Trioxaquines Are New Antimalarial Agents Active on All Erythrocytic Forms, Including Gametocytes. Antimicrob. Agents Chemother. 51: 1463-1472 [Abstract] [Full Text]  
  • Borrmann, S., Lundgren, I., Oyakhirome, S., Impouma, B., Matsiegui, P.-B., Adegnika, A. A., Issifou, S., Kun, J. F. J., Hutchinson, D., Wiesner, J., Jomaa, H., Kremsner, P. G. (2006). Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with Plasmodium falciparum Malaria.. Antimicrob. Agents Chemother. 50: 2713-2718 [Abstract] [Full Text]  
  • Borrmann, S., Adegnika, A. A., Moussavou, F., Oyakhirome, S., Esser, G., Matsiegui, P.-B., Ramharter, M., Lundgren, I., Kombila, M., Issifou, S., Hutchinson, D., Wiesner, J., Jomaa, H., Kremsner, P. G. (2005). Short-Course Regimens of Artesunate-Fosmidomycin in Treatment of Uncomplicated Plasmodium falciparum Malaria. Antimicrob. Agents Chemother. 49: 3749-3754 [Abstract] [Full Text]  
  • Cassera, M. B., Gozzo, F. C., D'Alexandri, F. L., Merino, E. F., del Portillo, H. A., Peres, V. J., Almeida, I. C., Eberlin, M. N., Wunderlich, G., Wiesner, J., Jomaa, H., Kimura, E. A., Katzin, A. M. (2004). The Methylerythritol Phosphate Pathway Is Functionally Active in All Intraerythrocytic Stages of Plasmodium falciparum. J. Biol. Chem. 279: 51749-51759 [Abstract] [Full Text]  
  • Rodrigues Goulart, H., Kimura, E. A., Peres, V. J., Couto, A. S., Aquino Duarte, F. A., Katzin, A. M. (2004). Terpenes Arrest Parasite Development and Inhibit Biosynthesis of Isoprenoids in Plasmodium falciparum. Antimicrob. Agents Chemother. 48: 2502-2509 [Abstract] [Full Text]  
  • Ramharter, M., Noedl, H., Winkler, H., Graninger, W., Wernsdorfer, W. H., Kremsner, P. G., Winkler, S. (2003). In Vitro Activity and Interaction of Clindamycin Combined with Dihydroartemisinin against Plasmodium falciparum. Antimicrob. Agents Chemother. 47: 3494-3499 [Abstract] [Full Text]  
  • Wellems, T. E. (2002). Plasmodium Chloroquine Resistance and the Search for a Replacement Antimalarial Drug. Science 298: 124-126 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»